What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?  

The practical considerations for incorporating bispecific antibodies into the treatment of relapsed DLBCL is the awareness of the potential side effects, although less than CAR T-cell therapy, in regards to the risk of cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity...

Bispecific antibodies are a very effective class of agents for lymphoma, including relapsed DLBCL. However, it is unclear whether they offer curative-intent therapy, and so I still typically sequence CAR T prior to bispecific antibodies, except in cases where patients absolutely cannot receive CAR T...